About JLK
-
- ourney of
-
- ife with
-
- nowledge
Journey of Life with Knowledge
- JLK accompanies journey of life with knowledge.
-
JLK is driving innovation in the medical AI industry with outstanding technology and expertise in the brain area.
We are pioneering the new medical paradigm with AI technology and establishing innovative medical data analytics and healthcare delivery system.
JLK by the Numbers
-
1 stWorld's Unique Brain Disorder Total Solution
AI medical solutions for ischemic stroke, hemorrhagic stroke, brain aneurysm, dementia using various medical imaging modalities, ie. CT, CTP, MRI, MRA
-
1 stLeader of AI Medical Industry
The 1st fourth industrial technology, The 1st medical AI company publicly listed
-
60 +Global Certificates
AI medical device licences from South Korea(MFDS), Japan (PMDA), Europe CE, Thai FDA, and across the world
-
110 +Core Technology Patents
Technological defense via AI medical device patents with constant R&D activities
Patent Registration No. 10-1740464 (Stroke diagnosis & prognosis forecast) -
11 +Stroke Total Solution for Overall Diagnostic Protocol
AI-based total stroke solution for patients in emergency and in treatment through analysis of various types of medical images such as CT, MRI, MRA
-
23 +Global R&D Network
Development and commercialization of neuro & cancer solutions via establishing global business network with more than 23 university hospitals
Securing high-quality medical imaging data and conducting clinical testing for AI accuracy improvement through various contracts
OUR MISSION
-
-
-
CHALLENGE
We strive for the best from challenging beyond impossibility.
-
-
-
-
CONTRIBUTION
We try our best to contribute to humanity's benefit with technology.
-
-
-
-
EXPANSION
We respond to various future market changes through AI.
-
KEEP CHALLENGING BEYOND IMPOSSIBILITY
We will quantum leap to be the global #1 AI company with incessant development and challenges.
JLK group
| Company Name |
JLK, Inc. |
|---|---|
| CEO |
Dongmin Kim, Ph.D. |
| Type of Business |
Application software |
| Main Business |
AI-based medical platform, AI-based medical data management platform business |
| Type of Entity |
SME, Start-up, External audit corporation, R&D Center, Designated entity for military service, Korea Innovative Medical Device Company, KOSDAQ Listed company(Dec. 2019) |
| Date of Establishment |
Feb. 14, 2014 |
| Headcount |
90+ |
| Location |
06141 JLK Tower, 5 Teheranro 33-Gil, Gangnam-Gu, Seoul, South Korea |
A World-class R&D Advisory Group
JLK is cooperating with our advisory group consisting of world's best experts of each research field.
-
Prof. Dong-Eog Kim, M.DAlma Mater: Seoul NationalUniversity, College of Medicine
Dongguk University, Ilsan Hospital
- Award
- 2015 Presidential Commendation
(Completion of Korea Institute of Brain Science)
-
Prof. Hee-Joon Bae, M.D.Alma Mater: Seoul National University, College of Medicine
Bundang Seoul National University Hospital
- Speacialty
- Stroke, Cardiovascular Disorders
-
Prof. Oh Young Bang, M.D.Alma Mater: Yonsei University,College of Medicine
Professor at Samsung SeoulHospital
- Specialty
- Cerebral infarction, Brain Stroke
-
Prof. Young Soon Yang, M.D.Research Professor at Duke-NUS National Neuroscience Institute
Soon Chun Hyang University Hospital, Department of Neurology
- Specialty
- Dementia, Neuropathy
-
Prof. Beom Joon Kim, M.D.Alma Mater: Seoul NationalUniversity, College of Medicine
Bundang Seoul National University Hospital
- Specialty
- Neuroscience, Ischemic Stroke, Stroke, Dementia
-
Prof. Jong-Won Chung, M.D.Alma Mater: Seoul NationalUniversity, College of Medicine
Professor at Samsung Seoul Hospital
- Specialty
- Brain Stroke
-
Prof. Jung Gon Kim, M.D.Alma Mater: Yonsei University,College of Medicine
Professor at Samsung Seoul Hospital
-
Prof. Ewert Bengtsson, Ph.D.Professor Emeritus at Departmentof IT, Uppsala University (Sweden)
Founder of CBA Center forImage Analysis
- Specialty
- Image Analysis
-
Prof. Nam Eik Jo, Ph.D.Alma Mater: Seoul National University,College of Engineering
Professor at Seoul National University,Department of Electrical InformationEngineering
- Specialty
- Digital Signal Processing
-
Prof. Hyung Eil Ku, Ph.D.Alma Mater: Seoul National University,College of Engineering
Professor at Ajou University, Department of Electronic of Engineering
- Specialty
- Machine Learning
-
Prof. Hosung Kim, Ph.D.Alma Mater: McGill University (Canada)
Professor of Neurology at USC (USA)
- Specialty
- Machine Learning
in Neuroimaging
JLK BIO
JLK BIO team, including the CEO, consists of drug discovery experts with a great deal of experience at global and local pharmaceutical companies.
With the expertise and experiences, the JLK BIO team is committed to drug discovery research and development with the AI-based drug discovery and development platform called, 'DeepHits'.
With JLK’s know-how from AI-driven medical solutions and JLK BIO’s new drug discovery technology, we hope to create a great synergy and build long-term growth.
LEADING AI HEALTHCARE INDUSTRY WITH NEURO & CANCER TECHNOLOGY
With the spirit of challenge and technology overcoming impossibility, we are growing fast to pioneer innovative technologies for conquering Neurological Diseases and Cancer.
- ~Present
-
2022. 10
In Malaysia, a total of 6 licenses of AI medical solutions obtained including 2 stroke solutions
JBS-01K, an artificial intelligence-based stroke diagnosis solution, designated as 'Digital Healthcare Medical Device Demonstration Support Project'
-
2022. 07
Brain aging analysis solution has been approved by the Ministry of Food and Drug Safety in Thailand
-
2022. 06
Exclusive sales contract with Japan's largest remote diagnostic company "DoctorNet" for our lung disease solution (MEDIHUB CXR)
Largest number of orders at the medical AI clinic business consortium, supplies of more than 35 solutions to 14 major hospitals nationwide.
-
2022. 05
AI-based stroke diagnosis solution JBS-01K obtained medical device license from the Ministry of Food and Drug Safety in Thailand
-
2022. 04
JBS-01K, neural image, computer aided detection/diagnosis software designated as a innovative medical device by the Ministry of Health and Welfare of Korea
-
2022. 01
Innovative medical device company designated by the Ministry of Health and Welfare of Korea
- 2021~
-
2021. 12
Acquired Japanese PMDA approval for chest X-ray image analysis solution JVIEWER-X
-
2021. 08
Established a subsidiary company, 'JLK BIO'
Acquired Thai medical device certification for chest X-ray image analysis solution JVEIWER-X
Acquired KFDA certification for brain aneurysm detection solution JBA-01K
-
2021. 06
Registered as Genetic Testing Service Agency
-
2021. 05
Won a national R&D project to develop AI Cancer analysis solution based on digital pathology (size worth ₩ 45bil)
Acquired Regulatory Sandbox approval to provide telemedicine services to Koreans living abroad
-
2021. 04
Acquired KFDA approval for prostate cancer analysis solution JPC-01K
-
2021. 03
Selected as Data Voucher project supplier company (2-year consecutive) by K-Data
-
2021. 02
Acquired Indonesian medical device certifications for 3 products including brain stroke analysis solution JBS-01K
- 2020~
-
2020. 12
Acquired Europe CE certification for chest X-ray image analysis solution JVIEWER-X
Hello Health applied to COVID-19 telemedicine center in Busan
-
2020. 09
Contract to supply AI solutions to Euijeongbu Eulji Smart Hospital
-
2020. 08
Acquired Turkish medical device certifications for 7 products including chest X-ray image analysis solution JVIEWER-X
-
2020. 07
Hello Health acquired KFDA U-Healthcare Gateway certification
-
2020. 05
Acquired 7 New Zealand medical device registration certifications
Acqruied KFDA certifications for 3 products including hemorrhagic stroke detection solution JBS-04A
Acquired KFDA certifications for 2 products including fundus image analysis solution JOD-01A
Acquired Australian certification for software as a medical device
-
2020. 03
Changed company name to JLK, Inc.
-
2020. 02
Acquired KFDA certification for prostate cancer pathology image analysis solution JDP-01A
-
2020. 01
Acquired European CE certification for breast cancer detection solution JBD-01K
Acquired KFDA certification for 2 products including Chest X-ray image analysis solution JVIEWER-X
- 2019~
-
2019. 12
IPO on KOSDAQ market (1st company to go public in the artificial intelligence medical industry)
Selected as No.1 Lung Abnormalities Diagnosis Solution in Clinton Health Access Initiative (CHAI) International Bidding Project
Received an award by the Minister of Ministry of Science Information and Communication
-
2019. 10
Acquired Vietnamese medical device certification for dementia/brain aging analysis solution ATROSCAN
Acquired KFDA certifications for 2 products including colon endoscopy analysis solution JFD-01K
Acquired KFDA certification for chest CT image analysis solution JLD-01K
-
2019. 09
Acquired European CE certifications for 4 products including dementia / brain aging analysis solution ATROSCAN
-
2019. 08
Acquired KFDA certification for demential / brain aging analysis solution ATROSCAN
-
2019. 07
Established a local subsidiary in Tokyo, Japan (JLK Inspection Japan)
Acquired Vietnamese medical device certification for brain stroke analysis solution JBS-01K
-
2019. 05
Established a local subsidiary in Silicon Valley, USA (JLK Inspection USA)
Commercialization of AI based TB Screening solution at South African Mine (Nominated as the Winner of a Global Competition)
Acquired European CE certifications for 2 products including prostate cancer analysis solution JPC-01K
-
2019. 04
Investment of 20 billion won by 5 VCs (Series C)
-
2019. 02
Material Transfer Agreement (MTA) with University of Missouri Hospital for Clinical Trial
- 2018~
-
2018. 11
Received award by the Minister of Ministry of Health and Welfare
-
2018. 08
Acquired KFDA class III medical device certification for AI-based brain stroke analysis solution (Korea's 1st AI-based KFDA class 3 medical device)
Acquired KFDA approval for brain stroke analysis solution JBS-01K
-
2018. 05
Received a certificate of excellence from the President of Health Industry Promotion Agency
-
2018. 02
Investment of 9.0 billion won by 6 institutions including KHIDI and VCs (Series B, 45x)
- 2017~
-
2017. 12
Selected as 'K-global 300 Company' by the Ministry of Science and ICT
-
2017. 11
Acquired Good Manufacturing Practice (GMP) certification for medical device manufacturing and quality management
-
2017. 03
Selected as 'Top 100 Next Generation Medical Device Company' by KFDA
-
2017. 01
Investment of 6.5 billion won from 5VCs (Series A, 25x)
- 2016~
-
2016. 03
Exclusive medical data license agreement with Korean Brain MR Data Center
- 2015~
-
2015. 08
Established Corporate R&D Center
-
2015. 05
Investment of 1.5 billion won by technology guarantee fund (Angel Fund, 20x)
- Since 2014
-
2014. 02
Established JLK Inspection Inc.